vs
Side-by-side financial comparison of Inhibikase Therapeutics, Inc. (IKT) and Pineapple Financial Inc. (PAPL). Click either name above to swap in a different company.
Inhibikase Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $707.3K, roughly 1.5× Pineapple Financial Inc.). Inhibikase Therapeutics, Inc. runs the higher net margin — -1223.3% vs -2756.2%, a 1532.9% gap on every dollar of revenue.
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
IKT vs PAPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $707.3K |
| Net Profit | $-12.7M | $-19.5M |
| Gross Margin | — | 48.9% |
| Operating Margin | -1323.3% | -2518.8% |
| Net Margin | -1223.3% | -2756.2% |
| Revenue YoY | — | -4.8% |
| Net Profit YoY | -5.0% | -3174.1% |
| EPS (diluted) | $-0.10 | $-1.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $707.3K | ||
| Q4 25 | $1.0M | $721.7K | ||
| Q3 25 | $0 | $730.5K | ||
| Q2 25 | $0 | $746.9K | ||
| Q1 25 | $0 | $743.3K | ||
| Q4 24 | $0 | $766.1K | ||
| Q3 24 | $0 | $598.3K | ||
| Q2 24 | $0 | $736.4K |
| Q1 26 | — | $-19.5M | ||
| Q4 25 | $-12.7M | $-6.4M | ||
| Q3 25 | $-11.9M | $-1.8M | ||
| Q2 25 | $-9.9M | $-557.7K | ||
| Q1 25 | $-13.7M | $-595.4K | ||
| Q4 24 | $-12.1M | $-656.9K | ||
| Q3 24 | $-5.8M | $-1.7M | ||
| Q2 24 | $-5.0M | $-848.6K |
| Q1 26 | — | 48.9% | ||
| Q4 25 | — | 49.6% | ||
| Q3 25 | — | 27.8% | ||
| Q2 25 | — | 67.6% | ||
| Q1 25 | — | 43.4% | ||
| Q4 24 | — | 45.9% | ||
| Q3 24 | — | 43.2% | ||
| Q2 24 | — | 44.2% |
| Q1 26 | — | -2518.8% | ||
| Q4 25 | -1323.3% | -909.1% | ||
| Q3 25 | — | -131.3% | ||
| Q2 25 | — | -93.3% | ||
| Q1 25 | — | -80.6% | ||
| Q4 24 | — | -90.5% | ||
| Q3 24 | — | -232.8% | ||
| Q2 24 | — | -121.7% |
| Q1 26 | — | -2756.2% | ||
| Q4 25 | -1223.3% | -891.6% | ||
| Q3 25 | — | -250.3% | ||
| Q2 25 | — | -74.7% | ||
| Q1 25 | — | -80.1% | ||
| Q4 24 | — | -85.7% | ||
| Q3 24 | — | -283.9% | ||
| Q2 24 | — | -115.2% |
| Q1 26 | — | $-1.21 | ||
| Q4 25 | $-0.10 | $-4.79 | ||
| Q3 25 | $-0.13 | $-0.93 | ||
| Q2 25 | $-0.11 | $-0.05 | ||
| Q1 25 | $-0.15 | $-1.73 | ||
| Q4 24 | $0.88 | $-2.60 | ||
| Q3 24 | $-0.65 | $-11.10 | ||
| Q2 24 | $-0.66 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $172.9M | $27.1M |
| Total Assets | $181.2M | $48.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $218.3M | — | ||
| Q3 25 | $39.1M | — | ||
| Q2 25 | $9.9M | — | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | $138.6M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $4.9M | — |
| Q1 26 | — | $27.1M | ||
| Q4 25 | $172.9M | $-5.5M | ||
| Q3 25 | $72.9M | $906.7K | ||
| Q2 25 | $80.1M | $842.6K | ||
| Q1 25 | $85.7M | $739.7K | ||
| Q4 24 | $94.9M | $1.3M | ||
| Q3 24 | $-530.6K | $1.3M | ||
| Q2 24 | $5.1M | $2.0M |
| Q1 26 | — | $48.9M | ||
| Q4 25 | $181.2M | $10.6M | ||
| Q3 25 | $79.6M | $5.4M | ||
| Q2 25 | $88.9M | $4.7M | ||
| Q1 25 | $94.3M | $4.0M | ||
| Q4 24 | $98.6M | $4.1M | ||
| Q3 24 | $4.4M | $4.1M | ||
| Q2 24 | $8.8M | $4.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.5M | $-3.3M |
| Free Cash FlowOCF − Capex | — | $-3.3M |
| FCF MarginFCF / Revenue | — | -462.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-3.3M | ||
| Q4 25 | $-7.5M | $-489.7K | ||
| Q3 25 | $-10.6M | $-507.6K | ||
| Q2 25 | $-5.6M | $397.0K | ||
| Q1 25 | $-4.1M | $-172.6K | ||
| Q4 24 | $-5.3M | $-663.6K | ||
| Q3 24 | $-4.9M | $-264.7K | ||
| Q2 24 | $-5.1M | $123.0K |
| Q1 26 | — | $-3.3M | ||
| Q4 25 | — | $-491.7K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-4.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-264.7K | ||
| Q2 24 | — | $122.7K |
| Q1 26 | — | -462.7% | ||
| Q4 25 | — | -68.1% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -44.2% | ||
| Q2 24 | — | 16.7% |
| Q1 26 | — | 0.0% | ||
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
